Cyclolignans as inhibitors of the insulin-like growth factor-I receptor [2]

Cancer Research

Volumn 67, Issue 6, 2007, Pages 2899-2900

  Larsson, Olle ^a   Axelson, Magnus ^b  

^a Karolinska Krankenhaus   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN RECEPTOR; LIGNAN DERIVATIVE; PICROPODOPHYLLIN; PODOPHYLLOTOXIN; SOMATOMEDIN C RECEPTOR; TUBULIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER; CELL CYCLE; CELL DEATH; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG TOLERABILITY; FIBROBLAST; GROWTH INHIBITION; IC 50; IN VIVO STUDY; LETTER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; XENOGRAFT;

EID: 34047249794     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-3659     Document Type: Letter

References (5)

1. Girnita A, Girnita L, del Prete F, Bartolazzi A, Larsson O, Axelson M. Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth. Cancer Res 2004;64:236-42.
2. Menu E, Jernberg-Wiklund H, Strömberg T, et al. Inhibiting the IGF-1 receptor tyrosine kinase with the cyclohgnan PPP: an in vitro and in vivo study in the 5T33MM mouse model. Blood 2006;107:655-60. Epub 2005 Jul 26.
3. Desbene S, Giorgi-Renault S. Drugs that inhibit tubulin polymerization: the particular case of podophyllotoxin and analogues. Curr Med Chem Anti-Cane Agents 2002;2:71-90.
4. Rosengren L, Vasilcanu D, Vasilcanu R, et al. IGF-1R tyrosine kinase expression and dependency in clones of IGF-1R knockout cells (R-). Biochem Biophys Res Commun 2006;347:1059-66. Epub 2006 Jul 12.
5. Dupont J, Pierre A, Froment P, Moreau C. The insulin-like growth factor axis in cell cycle progression. Horm Metab Res 2003;35:740-50.